AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipelinebenzinga_article·23 hours agoACIU+7.77%
AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764PUBT·1 day ago, 06:00 AMACIU+7.77%
AC Immune (NASDAQ:ACIU) Stock Passes Above 50-Day Moving Average - Here's WhyMarket Beat·2 days ago, 02:00 AMACIU+7.77%GS-C-0.18%
AC Immune wins FDA fast-track status for Parkinson’s immunotherapy ACI-7104PUBT·Aug 11 at 06:00 AMACIU+7.77%
AC Immune (NASDAQ:ACIU) Announces Earnings Results, Misses Estimates By $0.09 EPSMarket Beat·Aug 5 at 01:56 PMACIU+7.77%
AC Immune IFRS net loss narrows to CHF 12.93 million in H1 FY26; revenue rises to CHF 16.23 millionPUBT·Aug 5 at 06:01 AMACIU+7.77%TAK+0.28%
AC Immune (NASDAQ:ACIU) Shares Cross Below 50 Day Moving Average - Should You Sell?Market Beat·Aug 5 at 04:00 AMACIU+7.77%
AC Immune to present early human data for first-in-class TDP-43 PET tracer at AAIC 2026PUBT·Jul 7 at 06:01 AMACIU+7.77%
AC Immune Shareholders Back Capital Band, Governance Slate and Pay Caps at June 11 AGMTip Ranks·Jun 11 at 04:29 PMACIU+7.77%
AC Immune Reports Positive Phase 1 Data For PET Tracer ACI-19626 In Diagnosing ALSnasdaq·May 26 at 06:20 AMACIU+7.77%
